#wAIHA
I’m actually worried I’ve had MS symptoms for years and have been chalking it up to my wAIHA, like my heat sensitivity that makes me slur my speech and have heavy tingly legs
November 16, 2026 at 1:11 PM
do you guys remember when I was dating that ER doctor and then I got really sick with wAIHA and he dumped me while I was in the hospital because “it’s just too hard to be with you if you’re going to be this sick”?

anyways, my husband has been huge for my healing from that experience
November 15, 2026 at 8:28 PM
I have wAIHA so I get my blood checked at least monthly and it’s been nice and healthy!
November 16, 2026 at 1:12 PM
#$HCM just received China approval for SYVIK, an oral inhibitor treating chronic ITP and wAIHA with strong Phase II/III data supporting efficacy and safety.
November 19, 2026 at 1:01 PM
Read an excerpt from the latest @ashclinicalnews.bsky.social webinar in the mid-November issue!🔗 ➡️ https://bit.ly/4sZJIth

@ash.hematology.org
November 13, 2026 at 2:00 PM
For patients with #wAIHA, treatment with #nipocalimab resulted in durable hemoglobin response in 23.7%, as well as nominal improvements in fatigue scores and acceptable safety, indicating it could be an effective therapy for a disease with no current SOC: https://ow.ly/r4E35105cEq
November 10, 2026 at 4:00 PM
$CGEM — Velinotamig: FDA and Australia cleared Phase 1b/2a in ITP and wAIHA.

Information only — not investment advice.

https://www.merlintrader.com/cullinan-therapeutics-cgem-stock-hub/
October 27, 2026 at 4:28 PM
#CGEM Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance…

https://www.stocktitan.net/news/CGEM/cullinan-therapeutics-advances-velinotamig-into-global-clinical-215cwpw9ndr2.html?utm_source=stocktitan-bluesky&utm_medium=social
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
Cullinan Therapeutics (Nasdaq: CGEM) received U.S. and Australian regulatory clearance to initiate a global Phase 1b/2a trial of velinotamig.The open-label, multicenter study covers adults with relapsing and refractory immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA), disorders involving destruction of platelets or red blood cells. It will evaluate four doses injected under the skin. Part A tests ascending doses; Part B evaluates selected regimens in separate disease groups. Primary objectives assess safety, tolerability and effects on disease activity.Velinotamig is designed to direct T cells against BCMA-expressing cells, including antibody-producing plasma cells. Genrix Bio will present autoimmune-disease clinical data on November 8, 2026; Cullinan expects updated results from the ongoing refractory systemic lupus erythematosus study to further inform this approach.
www.stocktitan.net
October 27, 2026 at 11:00 AM
3/6 The ACS trial (PEARL) was withdrawn; ianalumab was pulled from ITP and wAIHA indications; LNP023 terminated in active lupus nephritis.
October 16, 2026 at 1:25 PM
In recent news, Imaavy (nipocalimab-aahu) becomes the first approved treatment for warm autoimmune hemolytic anemia (wAIHA). Another major win to tackling orphan diseases! www.reactiondigest.com/Biochemistry...

#chemistry #pharmaceuticals #news #biotech #science #biology #medicine
Imaavy (Nipocalimab-aahu) for Warm Autoimmune Hemolytic Anemia (wAIHA)
Imaavy® (nipocalimab-aahu) becomes the first approved treatment for warm autoimmune hemolytic anemia (wAIHA). Original post Oct 4, 2026. Last updated:
www.reactiondigest.com
October 4, 2026 at 6:52 AM
Complement activation. Chronic inflammation. Immune-meditated pathways across cytopenias.

Tomorrow, join a free webinar to learn how targeting shared immune mechanisms may improve outcomes in #ITP, #wAIHA, and beyond.

📅 Sept 30 · 10 AM EDT
Register at👇
https://ow.ly/UmIN50ZSEs1
September 29, 2026 at 4:01 PM
Complement activation. Chronic inflammation. Shared mechanisms across cytopenias.

In a free webinar, learn how a pathway-based approach can sharpen your clinical management of #ITP, #wAIHA, and beyond.

📅 Sept 30 · 10 AM EDT
Register at 👇
https://ow.ly/ck1s50ZPIfv

#Hematology
September 22, 2026 at 4:01 PM
Warm Autoimmune Hemolytic Anemia Market: Size, Growth, and Strategic Insights

The Warm Autoimmune Hemolytic Anemia (WAIHA) market is witnessing dynamic shifts fueled by advancements in therapeutics and growing patient awareness.
www.coherentmi.com/industry-rep...
Warm Autoimmune Hemolytic Anemia WAIHA Market Trends, 2032
Warm Autoimmune Hemolytic Anemia WAIHA Market size is growing with a CAGR of 5.50% & it crosses USD 7.24 Bn by 2032 from USD 4.98 Bn in 2025
www.coherentmi.com
September 11, 2026 at 12:29 PM
Warm Autoimmune Hemolytic Anemia Market Growth and Strategic Outlook 2026-2033

The Warm Autoimmune Hemolytic Anemia (WAIHA) market is witnessing steady expansion globally due to advancements in therapeutic interventions.
www.coherentmi.com/industry-rep...
Warm Autoimmune Hemolytic Anemia WAIHA Market Trends, 2032
Warm Autoimmune Hemolytic Anemia WAIHA Market size is growing with a CAGR of 5.50% & it crosses USD 7.24 Bn by 2032 from USD 4.98 Bn in 2025
www.coherentmi.com
September 11, 2026 at 11:10 AM
reposting in honor of the first treatment for wAIHA being approved

may I never have to take corticosteroids again 🙏🏼
like this is fascinating to me! the first pic is not even 2 years ago when I was on 60mg of prednisone every day and the second pic I took today after work lol
August 28, 2026 at 1:47 PM
yes! I actually worked on the first FcRn inhibitor for MG, and I remember telling the development team that we should study it in wAIHA, and while that team didn’t end up doing it, I’m really glad that J&J did!
August 28, 2026 at 1:37 PM
Imaavy secures expanded FDA approval as the first targeted treatment for warm autoimmune hemolytic anemia (wAIHA) in patients 12 and older.
Imaavy FDA Approval: First Ever Treatment for Rare Blood Disorder wAIHA 2026 - GlobalePrism
Imaavy secures expanded FDA approval as the first targeted treatment for warm autoimmune hemolytic anemia (wAIHA) in patients 12 and older.
globaleprism.com
August 26, 2026 at 1:45 PM
in wAIHA, hemolysis happens at body temp and above

there is another rare blood disease called cold agglutinin disease where hemolysis is triggered by cold temperatures, so that’s where the distinction is helpful
August 25, 2026 at 3:44 PM
Imaavy FDA Approval: First Ever Treatment for Rare Blood Disorder wAIHA 2026
August 25, 2026 at 6:11 PM
Buy $JNJ. Johnson & Johnson wins - Imaavy in wAIHA, TECVAYLI EU combo, Ottava clearance - de-risks pipeline, offsets talc noise. +15% 12m; market misprices derisk. I use @bluestocks.app analysi #finsky
August 25, 2026 at 7:04 PM
#JohnsonandJohnson has announced the #FDA has approved #Imaavy for the treatment of warm autoimmune haemolytic anaemia (#wAIHA) – a rare, life-threatening #autoantibodydisease – in adults and paediatric patients 12 years of age and older.

pharmaphorum.com/news/expande...
Expanded US Imaavy approval first ever for wAIHA
The FDA has approved Johnson & Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).
pharmaphorum.com
August 25, 2026 at 1:31 PM
J&J wins FDA label expansion for Imaavy in wAIHA
seekingalpha.com
August 25, 2026 at 11:45 AM
Didn't expect to read this before my coffee got cold! The FDA just approved IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia (wAIHA). That's when your immune system attacks your red blood cells.
FDA Approves IMAAVY® (nipocalimab-aahu) as First-Ever Treatment for Warm Autoimmune Hemolytic Anemia
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's IMAAVY® (nipocalimab-aahu) for adults and pediatric patients aged 12 and older with warm autoimmune hemolytic anemia (wAIHA
kfgo.com
August 25, 2026 at 2:01 AM